Active Ingredient History
Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. Mometasone inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis. ELOCON Lotion (Mometasone) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenoidectomy (Phase 4)
Adenoids (Phase 4)
Allergy and Immunology (Phase 3)
Alopecia Areata (Early Phase 1)
Anemia, Sickle Cell (Phase 2)
Anosmia (Phase 3)
Asthma ()
Breast Neoplasms (Phase 3)
Choanal Atresia (Phase 4)
Conjunctivitis (Phase 3)
COVID-19 (Phase 3)
Dermatitis, Atopic (Phase 4)
Dermatology (Phase 3)
Eczema (Phase 4)
Enuresis (Phase 4)
Eosinophilic Esophagitis (Phase 2)
Healthy Volunteers (Phase 1)
Hypersensitivity (Phase 3)
Inflammation (Phase 2)
Nasal Obstruction (Phase 4)
Nasal Polyps (Phase 4)
Olfaction Disorders (Phase 3)
Otitis Media with Effusion (Phase 3)
Pemphigoid, Bullous (Phase 2)
Phimosis (Phase 4)
Pruritus (Phase 3)
Psoriasis (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Radiodermatitis (Phase 4)
Rhinitis (Phase 4)
Rhinitis, Allergic (Phase 4)
Rhinitis, Allergic, Perennial (Phase 4)
Sinusitis (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Sleep Apnea Syndromes (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
Sleep Wake Disorders (Phase 4)
Sneezing (Phase 3)
Snoring (Phase 4)
Spinal Cord Injuries (Phase 1)
Tonsillitis (Phase 4)
Vitiligo (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue